Assessing Scholar Rock After Clinical Trial News and a 41% Surge in the Last Month

• Ever wondered if Scholar Rock Holding might be a hidden gem or simply overpriced? Let’s break down the facts and find out what the numbers reveal.
• The stock has been on quite a ride lately, jumping 41.0% over the last 30 days and climbing an impressive 34.4% in the past year. However, it is still down 8.9% year-to-date.
• Recently, Scholar Rock Holding caught investor attention following news of positive progress in its clinical trials for neuromuscular disease treatments, as well as increased activity from institutional investors. These developments have spurred excitement about the company's future and are likely fueling the recent run-up in share price.
• Right now, Scholar Rock scores 2 out of 6 on our initial value checks, suggesting its current price may not be a bargain by every measure. In the following sections, we will explore the most common valuation approaches and discuss a more insightful way to analyze value by the end of this article.

Scholar Rock Holding scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Scholar Rock Holding Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow (DCF) model estimates what a company is worth today based on projections of how much cash it will generate in the future. These cash flows are "discounted" back to present value to account for time and risk.

Scholar Rock Holding currently reports a Free Cash Flow (FCF) of -$274.6 Million, meaning the company is not yet producing positive free cash. Analyst projections suggest that by 2029, FCF will reach $339 Million, with further growth extrapolated by Simply Wall St for subsequent years. The DCF model uses these projections to calculate the company's intrinsic value.

Based on a two-stage Free Cash Flow to Equity DCF analysis, the estimated intrinsic value for Scholar Rock is $199.47 per share. Compared to its current market price, this analysis implies the stock is 79.8% undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Scholar Rock Holding is undervalued by 79.8%. Track this in your watchlist or portfolio, or discover 918 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Scholar Rock Holding.

Approach 2: Scholar Rock Holding Price vs Book

The Price-to-Book (PB) ratio is a widely used valuation measure, particularly suited for evaluating biotech companies like Scholar Rock Holding that may not be consistently profitable yet but have substantial balance sheet value. This ratio helps investors gauge how much the market is paying relative to the company's net assets, which can be especially meaningful when profits are volatile or negative.

Market participants often pay a premium to book value when expecting higher future growth or when risk is perceived as lower. In contrast, a lower PB ratio can reflect cautious views on growth or greater risks. For Scholar Rock, the current PB ratio stands at 16.74x, which is significantly higher than both the industry average of 2.52x and the peer average of 8.26x.

Simply Wall St's proprietary "Fair Ratio" goes beyond just peer and industry comparisons by dynamically adjusting for critical factors such as a company's earnings growth, risks, profit margins, industry sector, and market capitalization. This approach better reflects what a reasonable PB multiple should be for Scholar Rock, given its unique profile and forward-looking prospects.

Based on the Fair Ratio specifically calculated for Scholar Rock, the actual PB ratio of 16.74x is much higher. This suggests that at today's price, the company is currently priced above what its fundamentals would warrant.

Result: OVERVALUED

PB ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1422 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Scholar Rock Holding Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let's introduce you to Narratives. A Narrative is a simple yet powerful tool that allows you to create a story based on your personal perspective about a company, shaped by your assumptions for its future revenue, earnings, margins, and ultimately, fair value. Narratives connect what you believe about a company's future with clear financial forecasts, showing how your outlook translates into a valuation.

With Narratives on Simply Wall St's Community page, millions of investors can easily build and share these stories, making investing more transparent and collaborative. Narratives empower you to see at a glance whether Scholar Rock’s fair value, based on your expectations, suggests it is time to buy or sell compared to the current price. They also automatically refresh whenever new news or results emerge, so your forecasts are never out of date.

For example, one investor might believe Scholar Rock’s upcoming clinical trial success could mean a fair value as high as $210 per share, while another might be more cautious, estimating fair value closer to $60, all within the same Narrative tool.

Do you think there's more to the story for Scholar Rock Holding? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com